CLINICAL RESPONSE TO WARFARIN (ALDOCUMAR): CLINICAL EXOME PANEL (Sec. & CNVs) – 3 genes
Delivery time
3-4 weeks
Sample
Blood
The Warfarin Clinical Response Panel (Aldocumar) analyzes genetic variants that determine individual sensitivity to and metabolism of this oral anticoagulant, widely used in the prevention and treatment of deep vein thrombosis, pulmonary embolism, and cardioembolic events. It evaluates the CYP2C9, CYP4F2, and VKORC1 genes, which are fundamental to the metabolic and pharmacodynamic pathway of warfarin. Variants in CYP2C9 alter the rate of drug metabolism, while polymorphisms in VKORC1 modify its sensitivity, increasing the risk of bleeding or sub-anticoagulation depending on the dose. The CYP4F2 gene influences vitamin K metabolism, modulating the overall anticoagulant response. This study allows for personalized adjustment of the initial and maintenance doses, reducing complications and optimizing therapeutic efficacy.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€